Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02279420 · ClinicalTrials.gov registry record · NA

ESSENTIAL Trial™ Sham Cross-over

A NA study of Obesity, sponsored by USGI Medical.

Completed
Registry status
NA
Development phase
73
Enrollment target
11
Study locations

NCT02279420: Completed NA study of Obesity, sponsored by USGI Medical.

NCT02279420 is a NA study of Obesity that has completed, run by USGI Medical. The registered enrollment target is 73 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (91% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02279420, a NA study of Obesity, has completed, sponsored by USGI Medical.

COMPLETED
Registry status
NA
Development phase
73 participants
Enrollment target
11
Study locations

Study Summary

This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.

Primary Outcome

Percent total body weight loss calculated through 12 months post procedure

Conditions Studied

Interventions

  • DEVICE g-Cath EZ™ Suture Anchor Delivery Catheter

Study Locations (11)

Missouri

  • Saint Luke's Hospital - Kansas City
  • WA University School of Medicine - St Louis

Arizona

  • Shea Campus -Scottsdale Healthcare - Scottsdale

Florida

  • University of Miami Hospital - Miami

Georgia

  • Hamilton Medical Center - Dalton

Illinois

  • Northshore/Evanston Hospital - Evanston

Louisiana

  • Crescent City Surgical - Metairie

Massachusetts

  • Brigham & Women's Hospital - Boston

Minnesota

  • Fairview UMMC-University - Minneapolis

Trial Details

FieldValue
Enrollment Target 73 participants
Start Date 2015-01-05
Est. Completion 2016-09-30
Phase NA
USGI Medical

7 total trials

What the finished NCT02279420 record still lists

NCT02279420 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which g-Cath EZ™ Suture Anchor Delivery Catheter is the first listed.

NCT02279420 lists 11 locations in 10 states (Missouri, Arizona, Florida).

Frequently Asked Questions

What is clinical trial NCT02279420 about?

NCT02279420 is a clinical study titled "ESSENTIAL Trial™ Sham Cross-over". This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and e...

What is the current status of trial NCT02279420?

This trial is currently completed. It is a NA study. The enrollment target is 73 participants. The study started on 2015-01-05. Estimated completion is 2016-09-30.

What conditions does trial NCT02279420 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT02279420?

The interventions under investigation include: g-Cath EZ™ Suture Anchor Delivery Catheter (DEVICE).

Who is sponsoring clinical trial NCT02279420?

This trial is sponsored by USGI Medical, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02279420 being conducted?

This trial has 11 study locations across Arizona, Florida, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02279420's enrollment target sits among peer trials

73 576th of 1053 higher than 472 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03661307 · 73 participants · Phase 1

    Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

  • NCT05386108 · 73 participants · Phase 1

    Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

  • NCT05961592 · 73 participants · Phase 1

    R-2487 in Patients With Rheumatoid Arthritis

  • NCT06150664 · 73 participants · Phase 1

    A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02279420, the US trial registry maintained by the National Library of Medicine. NCT02279420 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.